Clicky

Tango Therapeutics(TNGX)

Description: Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.


Keywords: Biotechnology Cancer Life Sciences Biology Tumor Treatment Of Cancer Genetics Medical Genetics Applied Genetics Synthetic Lethality Oncogenomics

Home Page: www.tangotx.com

TNGX Technical Analysis

100 Binney Street
Cambridge, MA 02142
United States
Phone: 857 320 4900


Officers

Name Title
Dr. Barbara L. Weber M.D. Pres, CEO & Director
Ms. Daniella Beckman CPA Chief Financial Officer
Dr. Alan Huang Ph.D. Chief Scientific Officer
Dr. Alan Ashworth FRS, Ph.D. Founder & Member of Scientific Advisory Board
Dr. Levi Garraway M.D., Ph.D. Founder
Dr. William G. Kaelin Jr., M.D. Founder & Member of Scientific Advisory Board
Dr. Timothy K. Lu M.D., Ph.D. Founder
Dr. Antoni Ribas M.D., Ph.D. Founder & Member of Scientific Advisory Board
Mr. Douglas J. Barry Esq., J.D. Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Mr. John C. Ross M.S. VP of HR

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.5607
Price-to-Sales TTM: 28.8999
IPO Date: 2020-09-03
Fiscal Year End: December
Full Time Employees: 109
Back to stocks